BioSpace News Archive

Grant to fund ongoing preclinical research for important proof-of-principle non-human studies in preparation for human gene therapy clinical trials

Newly-Appointed CFO Andrew Schmidt Brings Extensive and Wide-Ranging Public Company Experience

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, August 4 , at 4:30 p.m. ET to discuss second quarter 2020 financial results and provide a general business update.

Gilead to Acquire 49.9% Equity Interest in Tizona – – Gilead Will Have Right to Acquire Remainder of Tizona for up to $1.25 Billion in Potential Option Fees and Future Milestone Payments – – Gilead Research and Development Funding to Accelerate Tizona’s First-in-Class Pipeline –

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale in a registered direct offering of 1,066,668 American Depositary Shares (“ADSs”), each re

Kepley BioSystems filed the second of two recent patents describing novel approaches to protective applications addressing the Coronavirus pandemic, as well as increasing antimicrobial resistance threats. Kepley researchers have invented a method to permanently infuse a substrate with antimicrobial functional fullerenes. Appli

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the proposed public offerings described below. The completion of the proposed public offerings is subject to market and other factors. BioNTech announced the commencement of a firm commitment underwritten offering (the “Underwritten Offering”) of 5,000,000 American Depositary Shares (“ADSs”), each representing one of its ordinary shares. In connection with the Underwri

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced the Company will participate in the upcoming mental health conferences: Elevate by Psych Congress Virtual Experience through July 25 -27. The conference brings together global mental health organizations and industry leaders, presenting a unique chance for professionals aro

Rafael Pharmaceuticals, Inc. announced that it has crossed the midpoint to its first interim analysis in enrollment for its pivotal Phase 3 clinical trial of CPI-613® for relapsed or refractory acute myeloid leukemia. The multicenter, open-label, randomized pivotal trial is evaluating the efficacy and safety of its lead compound devimistat in combination with high dose cytarabine and mitoxantrone in older patients.

AXIM ® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today it has welcomed Former Secretary of Veterans Affairs Peter O’Rourke to the Company’s Board of Directors. O’Rourke brings more than 20 years of experience serving in senior leadership roles in the public and private sectors. He has held leadership rol